Dark

Check out our API

XLO
Xilio Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Feb 3, 2026 10:31:18 AM EST

0.5600USD-4.425%(-0.0260)72,720

0.00Bid 0.00Ask 0.0000Spread

Pre-market

Feb 3, 2026 8:35:30 AM EST

0.5752USD-2.110%(-0.0124)6,703

After-hours

Jan 30, 2026 4:41:30 PM EST

0.6099USD+3.373%(+0.0199)0

Overview HistoricalExchangesShortsNews

Jan 20, 2022

07:39AM EST Xilio Therapeutics Doses First Patient In Phase 1/2 Clinical Trial Of XTX202 For Patients With Solid Tumors RTTNews

07:33AM EST Xilio Therapeutics Announces Initiation Of Patient Dosing In Phase 1/2 Clinical Trial Of XTX202 For The Treatment Of Patients With Solid Tumors Benzinga

07:30AM EST Xilio TherapeuticsAnnounces Initiation of Patient GlobeNewswire Inc

Jan 10, 2022

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2022 Benzinga

06:13AM EST HC Wainwright & Co. Initiates Coverage On Xilio Therapeutics with Buy Rating, Announces Price Target of $36 Benzinga

Jan 6, 2022

07:30AM EST Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Yuan Xu, Ph.D., to its board of directors. GlobeNewswire Inc

Dec 2, 2021

07:35AM EST Xilio Therapeutics Q3 EPS $(21.27) Up From $(24.19) YoY Benzinga

07:30AM EST Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 GlobeNewswire Inc

Nov 16, 2021

10:11AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021 Benzinga

07:22AM EST Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $31 Benzinga

06:56AM EST Cowen & Co. Initiates Coverage On Xilio Therapeutics with Outperform Rating Benzinga

06:40AM EST Morgan Stanley Initiates Coverage On Xilio Therapeutics with Overweight Rating, Announces Price Target of $32 Benzinga

Nov 15, 2021

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 12, 2021

07:00AM EST Xilio TherapeuticsAnnounces Preclinical Data GlobeNewswire Inc

Oct 26, 2021

04:05PM EDT Xilio Therapeutics Announces Closing of Initial Public Offering GlobeNewswire Inc

Oct 22, 2021

11:00AM EDT Xilio Therapeutics Shares Open For Trade At $15 Benzinga

07:36AM EDT The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs Benzinga

Share